Stefan Chiriac

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8377055/publications.pdf

Version: 2024-02-01

1039406 887659 28 323 9 17 citations h-index g-index papers 28 28 28 385 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Changes in Liver Steatosis Using Controlled Attenuation Parameter among Patients with Chronic Hepatitis C Infection Treated with Direct-Acting Antivirals Therapy Who Achieved Sustained Virological Response. Diagnostics, 2022, 12, 702.	1.3	8
2	Clinical and Laboratory Characteristics of Normal Weight and Obese Individuals with Non-Alcoholic Fatty Liver Disease. Diagnostics, 2022, 12, 801.	1.3	4
3	Ischemic Heart Disease and Liver Cirrhosis: Adding Insult to Injury. Life, 2022, 12, 1036.	1.1	1
4	Prognostic value of neutrophil-to-lymphocyte ratio in cirrhotic patients with acute-on-chronic liver failure. Turkish Journal of Gastroenterology, 2021, 31, 868-876.	0.4	10
5	SMALL-BOWEL CAPSULE ENDOSCOPY IN INFLAMMATORY BOWEL DISEASE TYPE UNCLASSIFIED. Inflammatory Bowel Diseases, 2021, 27, S11-S11.	0.9	O
6	Association between Nonalcoholic Fatty Liver Disease and Endocrinopathies: Clinical Implications. Canadian Journal of Gastroenterology and Hepatology, 2021, 2021, 1-8.	0.8	17
7	The Impact of the COVID-19 Pandemic on Gastrointestinal Endoscopy Activity in a Tertiary Care Center from Northeastern Romania. Healthcare (Switzerland), 2021, 9, 100.	1.0	15
8	Role of ammonia in predicting the outcome of patients with acute-on-chronic liver failure. World Journal of Clinical Cases, 2021, 9, 552-564.	0.3	9
9	Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter for the Diagnosis of Liver Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Diagnostics, 2021, 11, 787.	1.3	12
10	Hepatitis C Virus Prevalence and Risk Factors in a Village in Northeastern Romania—A Population-Based Screening—The First Step to Viral Micro-Elimination. Healthcare (Switzerland), 2021, 9, 651.	1.0	2
11	An update on direct antiviral agents for the treatment of hepatitis C. Expert Opinion on Pharmacotherapy, 2021, 22, 1729-1741.	0.9	26
12	Endocardial fibroelastosis and dilated cardiomyopathy – the past and future of the interface between histology and genetics. Romanian Journal of Morphology and Embryology, 2021, 61, 999-1005.	0.4	9
13	Pediatric nonalcoholic fatty liver disease – a changing diagnostic paradigm. Romanian Journal of Morphology and Embryology, 2021, 61, 1023-1031.	0.4	5
14	The Risk of Clostridioides difficile Infection in Cirrhotic Patients Receiving Norfloxacin for Secondary Prophylaxis of Spontaneous Bacterial Peritonitis—A Real Life Cohort. Medicina (Lithuania), 2021, 57, 964.	0.8	3
15	Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter. Canadian Journal of Gastroenterology and Hepatology, 2021, 2021, 1-11.	0.8	17
16	Did the severe acute respiratory syndrome-coronavirus 2 pandemic cause an endemic <i>Clostridium difficile</i> ii) infection?. World Journal of Clinical Cases, 2021, 9, 10180-10188.	0.3	5
17	The Prevalence of Liver Steatosis and Fibrosis Assessed by Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter in Apparently Healthy Romanian Medical Students. Diagnostics, 2021, 11, 2341.	1.3	6
18	Clinical Impact of Small Bowel Capsule Endoscopy in Obscure Gastrointestinal Bleeding. Medicina (Lithuania), 2020, 56, 548.	0.8	7

#	Article	IF	CITATIONS
19	Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: A Bidirectional Relationship. Canadian Journal of Gastroenterology and Hepatology, 2020, 2020, 1-5.	0.8	47
20	Immunoglobulin A Vasculitis Complicated with Clostridium difficile Infection: a Rare Case Report and Brief Review of the Literature. Journal of Gastrointestinal and Liver Diseases, 2020, 25, 235-238.	0.5	9
21	Nonalcoholic Fatty Liver Disease-Related Chronic Kidney Disease. Canadian Journal of Gastroenterology and Hepatology, 2020, 2020, 1-3.	0.8	4
22	Ulcerated intussuscepted jejunal lipoma-uncommon cause of obscure gastrointestinal bleeding: A case report. World Journal of Clinical Cases, 2019, 7, 3765-3771.	0.3	1
23	Split-dose or hybrid nonsteroidal anti-inflammatory drugs and N-acetylcysteine therapy for prevention of post-retrograde cholangiopancreatography pancreatitis. World Journal of Clinical Cases, 2019, 7, 300-310.	0.3	2
24	 i> Clostridium difficile $$ /i> infection in hospitalized octogen arian patients. Geriatrics and Gerontology International, 2018, 18, 315-320.	0.7	6
25	A Half Century of Endoscopic Retrograde Colangio Pancreatography: Reflections of the Past, Present and Future. Journal of Gastrointestinal and Liver Diseases, 2018, 27, 357-360.	0.5	4
26	Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older. Medicine (United States), 2017, 96, e9271.	0.4	17
27	Update on adrenal insufficiency in patients with liver cirrhosis. World Journal of Gastroenterology, 2013, 19, 445.	1.4	76
28	Gastrointestinal Manifestations of IgA Vasculitis-Henoch-Schönlein Purpura., 0,,.		1